CG Oncology, Inc. Common stock (CGON) Revenue History
Annual and quarterly revenue from 2021 to present
CGON Revenue Over Time (2021–2025)
CGON Revenue Growth History
3 of 4 years with positive growth- FY2021 revenue growth
- N/A
- FY2022 revenue growth
- -98.2%
- FY2023 revenue growth
- +6.8%
- FY2024 revenue growth
- +458.3%
- FY2025 revenue growth
- +254.7%
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2026 | $1.1M | +1982.7% |
| Q4 2025 | $2.3M | +409.2% |
| Q3 2025 | $1.7M | +3774.4% |
| Q2 2025 | $0 | -100.0% |
| Q1 2025 | $52K | -90.2% |
| Q4 2024 | $456K | +45500.0% |
| Q3 2024 | $43K | +377.8% |
| Q2 2024 | $111K | — |
Multi-year avg. share of annual revenue by fiscal quarter
Revenue Breakdown (FY 2025)
CGON's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
CGON Revenue Analysis (2021–2025)
Current Revenue & Growth
As of June 23, 2026, CG Oncology, Inc. Common stock (CGON) generated trailing twelve-month (TTM) revenue of $5.1 million, reflecting explosive growth of +1982.7% year-over-year. The most recent quarter (Q1 2026) recorded $1.1 million in revenue, down 53.4% sequentially.
Historical Growth Trajectory
CGON's historical revenue data shows a 3-year CAGR of +176.6%. CG Oncology, Inc. Common stock's highest annual revenue of $10.4 million was recorded in 2021.
Revenue by Segment
CGON's revenue is primarily driven by License And Collaboration Revenue (100%). With over half of revenue concentrated in License And Collaboration Revenue, the company has a focused business model while developing other growth vectors.
Peer Comparison
Compared to Healthcare sector peers — including GRVY (-54.0% YoY), TGTX (+81.3% YoY), and JANX (+131.5% YoY) — CGON has outperformed the peer group in revenue growth. Compare CGON vs GRVY →
CGON Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| CGONCurrent | $5M | +1982.7% | - | -4722.1% | |
 GRVY | $560.5B | -54.0% | +6.7% | 14.2% | |
 TGTX | $616M | +81.3% | +426.7% | 20.0% | |
 JANX | $10M | +131.5% | - | -1576.7% | |
 RCUS | $247M | +67.4% | +25.9% | -156.3% |
CGON Historical Revenue Data (2021–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $4.0M | +254.7% | $-607,000 | -15.0% | $-190,774,000 | -4722.1% |
| 2024 | $1.1M | +458.3% | $1.1M | 100.0% | $-114,666,000 | -10067.3% |
| 2023 | $204K | +6.8% | $204K | 100.0% | $-55,449,000 | -27180.9% |
| 2022 | $191K | -98.2% | $176K | 92.1% | $-35,246,000 | -18453.4% |
| 2021 | $10.4M | - | $10.3M | 99.9% | $-12,606,000 | -121.7% |
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
5+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
CGON — Frequently Asked Questions
Quick answers to the most common questions about buying CGON stock.
Is CGON's revenue growth accelerating or slowing?
CGON revenue growth is accelerating. TTM revenue reached $5M, up +1982.7% year-over-year — ahead of the 5-year CAGR of N/A. This indicates the business is expanding faster than its historical baseline.
What is CGON's revenue history from 2021 to 2026?
CG Oncology, Inc. Common stock (CGON) revenue history spans 2021 to 2026. TTM revenue as of 2026 is $5M, growing at +1982.7% YoY. The 5-year CAGR is N/A. Complete annual and quarterly revenue figures are available on this page, including gross profit, operating income, and margin trends.
What is CGON's long-term revenue growth rate (CAGR)?
CG Oncology, Inc. Common stock's 5-year revenue CAGR of N/A reflects the sustained nature of its business expansion. As of 2026, the current YoY growth rate of +1982.7% is above this long-term average. CAGR is the most reliable measure of sustained revenue momentum for CGON.
Why does CGON's quarterly revenue fluctuate?
CGON quarterly revenue can fluctuate significantly between periods. A quarter-over-quarter (QoQ) change does not always indicate a trend; comparing the same quarter year-over-year (YoY) is a more reliable signal for underlying growth. CG Oncology, Inc. Common stock's revenue data from 2021 to 2026 shows full historical quarterly detail on this page.
How is CGON's revenue distributed by segment?
CGON reports revenue broken down by product line and geographic region. The segment breakdown on this page shows which business units contribute the most to total revenue as of the latest fiscal year. Concentration in a single segment above 50% indicates category dependence, while a diversified mix signals more resilient revenue streams.
How does CGON's revenue compare to industry peers?
CG Oncology, Inc. Common stock (CGON) with TTM revenue of $5M and +1982.7% YoY growth can be benchmarked against sector peers using the comparison table on this page. Revenue growth relative to peers indicates market share gains or losses. The peer section shows TTM revenue, YoY growth, and operating margin for direct comparisons.